Example: barber
DIRECTIVE 2001/83/EC OF THE EUROPEAN PARLIAMENT …
stuffs or toilet preparations), and such disparities directly affect the functioning of the internal market. (5) Such hindrances must accordingly be removed; whereas this entails approximation of the relevant provisions. (6) In order to reduce the disparities which remain rules should be laid down on the control
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
Policy Statement on Expulsion and Suspension Policies In ...
www2.ed.govchildhood settings, including issues of racial/national origin/ethnic and sex disparities and ... This policy statement is part of a series of Federal actions that aim to prevent, severely reduce, and ultimately eliminate expulsion and suspension in early childhood settings, and …
Fact sheets on sustainable development goals: health ...
www.euro.who.int• Seat-belts reduce the risk of death in a crash by 61% when used correctly (3,5,6). Large disparities exist within the WHO European Region: the death rate from road traffic injuries is 8.6 times higher in the country with the highest rate than …
The Color of Justice - Sentencing Project
www.sentencingproject.orgdisparities is required in order to eliminate them. True progress towards a racially just system requires an understanding of the variation in racial and ethnic inequities in imprisonment across states and the policies and day-to-day practices that drive these inequities.6 This report documents the rates of incarceration for
Budget Review 2020 - National Treasury
www.treasury.gov.zacomparison with the 2019 Budget, government proposes to reduce its expenditure by R156.1 billion – primarily through a decrease in its compensation bill. Public‐service employees should be fairly remunerated, but government is obligated to balance its wage bill with the broader needs of …
Reducing Inequalities in Health
www.health.govt.nzthe overall health of New Zealanders and to reduce inequalities amongst New Zealanders, with a focus on Ma¯ori, Pacific peoples and low-income New Zealanders. Successful implementation of the New Zealand Health Strategy requires a population health approach. This approach takes into account all the factors that influence health and how
Crisis Standard of Care COVID-19 Pandemic
www.nursingworld.orgdisparities, a "first come first served" approach may compound existing injustice. Healthcare systems must counter these impacts with efforts to protect at-risk populations. • A range of contingencies must be planned for by accountable decisionmakers as demand for care increases and resources, such as staff and materiel, become scarce.